Circulating antibodies against c‐<i>MYC</i> oncogene product in sera of colorectal cancer patients

Ben-Mahrez, Kamel; Sorokine, Iréne; Thierry, Dominique; Kawasumi, Toshiyuki; Ishii, Shunsuke; Salmon, Rémy; Kohiyama, Masamichi

doi:10.1002/ijc.2910460109

Cited by 64 publications

(31 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results indicate that ECPKA might be a cancer antigen. There is increasing evidence that patients with cancer produce autoantibodies against antigens in their tumors (12)(13)(14)(15), suggesting that such autoantibodies could have diagnostic/prognostic value. We speculated that ECPKA excretion might elicit the induction of serum autoantibodies and that the presence of such autoantibodies could serve for cancer detection.…”

Section: Introductionmentioning

confidence: 99%

Autoantibody Cancer Biomarker: Extracellular Protein Kinase A

Nesterova¹,

Johnson²,

Cheadle³

et al. 2006

Cancer Research

View full text Add to dashboard Cite

In cancer cells, cyclic AMP-dependent protein kinase (PKA) is secreted into the conditioned medium. This PKA, designated as extracellular protein kinase A (ECPKA), is markedly upregulated in the sera of patients with cancer. The currently available tumor markers are based on the antigen determination method and lack specificity and sensitivity. Here, we present an ECPKA autoantibody detection method for a universal biomarker that detects cancer of various cell types. We tested sera from 295 patients with cancers of various cell types, 155 normal controls, and 55 patients without cancer. The specificity and sensitivity of this autoantibody enzyme immunoassay method were compared with the conventional antigen determination method by receiver-operating characteristic plots. In the sera, the presence of autoantibody directed against ECPKA was highly correlated with cancer. High anti-ECPKA autoantibody titers ( frequency, 90%; mean titer, 3.0) were found in the sera of patients with various cancers, whereas low or negative titers ( frequency, 12%; mean titer, 1.0) were found in the control group. The receiver-operating characteristic plot showed that autoantibody enzyme immunoassay exhibited 90% sensitivity and 88% specificity, whereas the enzymatic assay exhibited 83% sensitivity and 80% specificity. These results show that the autoantibody method distinguished between patients with cancer and controls better than the antigen method could. Our results show that autoantibody ECPKA is a universal serum biomarker for cancers of various cell types. (Cancer Res 2006; 66(18): 8971-4)

show abstract

Section: Introductionmentioning

confidence: 99%

Autoantibody Cancer Biomarker: Extracellular Protein Kinase A

Nesterova¹,

Johnson²,

Cheadle³

et al. 2006

Cancer Research

View full text Add to dashboard Cite

show abstract

“…Immunogenic tumor-associated antigens have been described primarily for malignant tumors including melanoma, breast cancer, colon cancer, ovarian cancer (Real et al, 1988;Ben-Mahrez et al, 1990;Gallagher et al, 1991;Disis et al, 1994;Disis and Cheever, 1996;Boon and Lloyd, 1997). However, dierent studies have indicated that meningiomas are also capable of inducing an immune response in the host.…”

Section: Introductionmentioning

confidence: 99%

MGEA6 is tumor-specific overexpressed and frequently recognized by patient-serum antibodies

et al. 2002

View full text Add to dashboard Cite

“…For example, the identification of mutant ras genes by polymerase chain reaction and direct sequencing of DNA isolated from the serum or plasma of three patients with pancreatic cancer has been described (89 (96). Antibodies to the myc protein have also been described in the sera of patients with myeloid leukemia and lymphoma, including Burkitt's lymphoma (97).…”

Section: Oncoproteins Growth Factor Receptorsmentioning

confidence: 99%

Biomarkers of gene expression: growth factors and oncoproteins.

Brandt‐Rauf

1997

Environ Health Perspect

View full text Add to dashboard Cite

This article reviews the literature on the application of methods for the detection of growth factors, oncogene proteins, and tumor-suppressor gene proteins in the blood of humans with cancer or who are at risk for the development of cancer. The research summarized here suggests that many of these biomarker assays can be used to distinguish between diseased and nondiseased states and in some instances may be able to predict susceptibility for future disease. Thus, these biomarkers could be valuable tools for monitoring at-risk populations for purposes of disease prevention and control. -Environ Health Perspect 105(Suppl 4): 807-816 (1997)

show abstract

Circulating antibodies against c‐MYC oncogene product in sera of colorectal cancer patients

Cited by 64 publications

References 11 publications

Autoantibody Cancer Biomarker: Extracellular Protein Kinase A

Autoantibody Cancer Biomarker: Extracellular Protein Kinase A

MGEA6 is tumor-specific overexpressed and frequently recognized by patient-serum antibodies

Biomarkers of gene expression: growth factors and oncoproteins.

Contact Info

Product

Resources

About